SHANDONG XINHUA (00719): Obtained the registration certificate for the mixed suspension of cetirizine carbonate.
Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced recently that the company has received the "Drug Registration Certificate" for the suspension of Carbocisteine Vilaum compound approved and issued by the National Medical Products Administration.
Shandong Xinhua (00719) announced that the company has recently received the Drug Administration approval and issuance of the drug registration certificate for the carbon sevelamer granules suspension (referred to as "this product").
This product is used to control hyperphosphatemia in adult patients with chronic kidney disease (CKD) undergoing dialysis treatment, as well as in adult patients with chronic kidney disease with serum phosphorus levels 1.78 mmol/L but not undergoing dialysis.
The carbon sevelamer granules suspension submitted by Shandong Xinhua Pharmaceutical has recently been approved, enriching the company's formulation product series and helping to enhance the company's overall competitiveness.
Related Articles
TRULY INT'L (00732) spent 911,400 Hong Kong dollars to repurchase 930,000 shares on June 1st.
CHINA BOTON (03318) spent 39,800 Hong Kong dollars on June 1 to repurchase 30,000 shares.
C STRATEGIC TEC (01725) May revenue is approximately 56.21 million yuan, an increase of about 82.32% year-on-year.
TRULY INT'L (00732) spent 911,400 Hong Kong dollars to repurchase 930,000 shares on June 1st.
CHINA BOTON (03318) spent 39,800 Hong Kong dollars on June 1 to repurchase 30,000 shares.
C STRATEGIC TEC (01725) May revenue is approximately 56.21 million yuan, an increase of about 82.32% year-on-year.
